文献速递胸部肿瘤放疗头颈部肿瘤放疗放疗物理与技术

质子放射治疗的保险审批流程:患者诊疗的显著障碍

The Insurance Approval Process for Proton Radiation Therapy: A Significant Barrier to Patient Care.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-12-14

本研究分析2013至2016年间一家大型质子治疗中心1753例胸部或头颈部肿瘤患者的保险审批与申诉结果。 Medicare与私人保险初次申请批准率分别为91%和30%,306例初次被拒者中276例申诉、189例(68%)拒赔被推翻。最终批准率87%,但审批流程耗时且与临床因素关联有限。

要点

  • Medicare(n=538)与私人保险(n=365)初次申请批准率分别为91%和30%,中位决定时间分别为3天和14天。
  • 306例初次被拒患者中276例申诉,189例(68%)拒赔被推翻,中位时间自初次询问起21天。
  • 多变量分析中Medicare是初次批准最强预测因素(OR 14.20,P<.001),2015至2016年较2013至2014年批准率下降(OR 0.54,P=.001)。

核心结论

  • 尽管质子治疗最终批准率达87%,保险流程仍是资源密集型障碍,并导致癌症治疗显著时间延迟。
  • 这些发现以及保险结果缺乏临床相关因素,凸显需要提高效率、透明度及利益相关方协作以促进及时患者诊疗和研究。

研究设计与样本

  • 2013至2016年间,一家大型质子治疗中心1753例胸部或头颈部肿瘤患者被考虑质子治疗,其中903例(553例胸部、350例头颈部)进入保险流程。
  • 计算批准率、批准时间及初次拒赔后申诉成功率,并通过逻辑回归评估临床因素与保险结果的关联。

主要发现

  • Medicare(n=538)与私人保险(n=365)初次申请批准率分别为91%和30%,自询问至决定的中位时间分别为3天和14天。
  • 306例初次被拒患者中276例申诉,189例(68%)拒赔被推翻,自初次询问起中位时间21天。
  • 多变量分析中,Medicare是初次批准最强预测因素(OR 14.20,P<.001);2015至2016年较2013至2014年批准率下降(OR 0.54,P=.001)。
  • 申诉患者多变量分析中,批准与临床试验入组或肿瘤类型无关联;提交显示正常组织剂量学优势的对比治疗计划(质子vs光子)与批准可能性降低相关(OR 0.43,P=.006),处方剂量≥66 Gy亦与批准可能性降低相关(OR 0.48,P=.019)。

关键数值与推荐

  • Medicare初次申请批准率91%(n=538),私人保险为30%(n=365)。
  • 初次拒赔申诉后拒赔被推翻率68%(189/276)。
  • Medicare预测初次批准的OR为14.20(P<.001)。
  • 2015至2016年较2013至2014年批准率OR为0.54(P=.001)。
  • 提交对比治疗计划与批准可能性降低相关,OR为0.43(P=.006);处方剂量≥66 Gy与批准可能性降低相关,OR为0.48(P=.019)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Proton therapy is increasingly prescribed for cancer treatment, given its potential for improvements in clinical outcomes and toxicity reduction; however, insurance coverage continues to be a barrier to patient access. This study examined insurance approval and appeal outcomes at a large-volume proton therapy center to clarify the process and identify areas for improvement. METHODS AND MATERIALS: In 2013 to 2016, 1753 patients with thoracic or head and neck cancer were considered for proton therapy; 903 (553 thoracic, 350 head and neck) entered the insurance process. Rates of and times to approval and successful appeal after initial denial were calculated. Clinical factors were evaluated for association with insurance outcomes via logistic regression. RESULTS: Approval rates by Medicare (n = 538) and private insurance (n = 365) were 91% and 30% on initial request, at a median 3 days and 14 days from inquiry to determination. Of the 306 patients initially denied coverage, 276 appealed the decision, and denial was overturned for 189 patients (68%; median time, 21 days from initial inquiry). On multivariable analysis, Medicare (odds ratio [OR], 14.20; P < .001) was the strongest predictor of initial approval. Approval rates decreased from 2013 to 2014 versus 2015 to 2016 (OR 0.54; P = .001). For patients who appealed denial, multivariable analysis found no associations between approval and trial enrollment or tumor type. Submission of a comparison treatment plan (proton vs photon) indicating dosimetric advantage to normal tissues was associated with decreased likelihood of approval (OR 0.43; P = .006), as was a prescribed dose of ≥66 Gy (OR 0.48; P = .019). CONCLUSIONS: Despite an 87% ultimate approval rate for proton therapy, the insurance process is a resource-intensive barrier to patient access associated with significant time delays to cancer treatment. These findings, plus the lack of clinical correlates with insurance outcomes, highlight a need for increased efficiency, transparency, and collaboration among stakeholders to promote timely patient care and research.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Ning MS, Gomez DR, Shah AK, et al. The Insurance Approval Process for Proton Radiation Therapy: A Significant Barrier to Patient Care. Int J Radiat Oncol Biol Phys. 2018. PMID: 30557675. doi:10.1016/j.ijrobp.2018.12.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。